Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer

Verzenio ™ (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced or metastatic breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news